ストックスクリーナーアプリを入手
8.86
1.56%
-0.14
アフターアワーズ：
8.86
前日終値:
$9.00
開ける：
$9.01
24時間の取引高:
1.52M
Relative Volume:
0.73
時価総額：
$1.15B
収益：
$745.97M
当期純損益:
$-99.21M
株価収益率:
-11.46
EPS:
-0.7729
ネットキャッシュフロー:
$-5.09M
1週間 パフォーマンス:
-1.77%
1か月 パフォーマンス:
+10.75%
6か月 パフォーマンス:
-15.05%
1年 パフォーマンス:
+13.01%
1日の値動き範囲:
$8.735
$9.085
1週間の範囲:
$8.18
$10.33
52週間の値動き範囲:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Compare NEO vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.86 | 1.17B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Chronicle-Journal
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
MSN Money - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Leerink upgrades NeoGenomics to Outperform, raises target to $25 - TipRanks
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 - marketscreener.com
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat - Investing.com UK
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat By Investing.com - Investing.com India
NeoGenomics Shares Jump on Earnings and Analyst Upgrades - Yahoo Finance
Leerink upgrades Neogenomics stock rating on oncology growth outlook - Investing.com
NeoGenomics upgraded to Buy from Hold at Benchmark - TipRanks
NeoGenomics stock surges following earnings, two upgrades By Investing.com - Investing.com South Africa
NeoGenomics stock surges following earnings, two upgrades - Investing.com
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Earnings Call Summary | NeoGenomics(NEO.US) Q1 2026 Earnings Conference - Moomoo
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth - TradingView
Benchmark upgrades NeoGenomics (NEO) - MSN
NeoGenomics Reports First Quarter 2026 Results - BioSpace
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth By Investing.com - Investing.com Australia
NeoGenomics Q1 2026 Earnings Call Transcript - MarketBeat
NeoGenomics, Inc. Reports Q1 2026 Financial Results and Provides Earnings Highlights - Minichart
NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c - TipRanks
NeoGenomics (NEO) Q1 2026 Earnings Transcript - The Motley Fool
NeoGenomics Q1 Earnings Call Highlights - MarketBeat
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth - Investing.com
Earnings call transcript: NeoGenomics Q1 2026 revenue beats forecast By Investing.com - Investing.com Canada
Earnings call transcript: NeoGenomics Q1 2026 revenue beats forecast - Investing.com
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
1.63%
大文字化:
|
ボリューム (24 時間):